Zoster-associated pain
Conditions
Interventions
D1E1 group:Conventional regimen + tDCS real stimulation (anode—F3, cathode—F4) + eszopiclone
D0E1 group:tDCS sham stimulation + eszopiclone
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. A diagnosis of zoster-associated pain (ZAP) meeting the criteria outlined in the Chinese Expert Consensus on the Diagnosis and Treatment of Herpes Zoster (2022 edition); 2. A diagnosis of insomnia according to the International Classification of Sleep Disorders, Third Edition (ICSD-3); 3. A total score of >5 on the Chinese version of the Pittsburgh Sleep Quality Index (PSQI), accompanied by significant daytime impairment (indicated by a score of >=2 on item 7 of the PSQI, 'Daytime Dysfunction'); 4. Age >=18 years;
Exclusion criteria
Exclusion criteria: 1. Presence of intracranial organic lesions or a history of craniocerebral trauma; 2. Current use of medications (e.g., naloxone) known to interfere with the analgesic effects of transcranial direct current stimulation (tDCS); 3. Coexisting acute or chronic pain attributable to other causes, such as gout, trauma, or post-surgical pain; 4. Diagnosis of a severe psychiatric disorder or chronic severe insomnia (defined as a condition lasting >3 months with an Insomnia Severity Index [ISI] score =22); 5. Comorbid sleep disorders, including sleep apnea, periodic limb movement disorder, parasomnias, or narcolepsy; 6. Significant dysfunction of vital organs (e.g., heart, liver, kidneys, or brain); 7. Presence of implanted medical devices, including cardiac pacemakers, brain stimulation devices, or intracranial metallic implants (e.g., aneurysm clips, cranial plates); 8. History of ventriculoperitoneal shunt placement; 9. Poorly controlled epilepsy; 10. Known allergy or severe adverse reactions to conventional antiviral drugs, central analgesics, or tricyclic antidepressants; 11. Cognitive impairment that precludes effective communication or independent completion of questionnaire assessments; 12. Conditions involving central nervous system depression or significant comorbidity, such as acute alcohol intoxication, impaired hepatic or renal function, myasthenia gravis, acute or predisposed angle-closure glaucoma, or severe chronic obstructive pulmonary disease; 13. Patient or family member refusal to participate in the study protocol;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pittsburgh Sleep Quality Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Insomnia Severity Index;Patient Health Questionnaire-9 score;Sleep parameters measured by Fitbit Charge 2?;Brief Pain Inventory score;7-item Generalized Anxiety Disorder Scale score;Pain Numerical Rating Scale score; | — |
Countries
China
Contacts
Public ContactChen Liping
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed